The value of the S100β marker in patients with COVID-19

Background. The purpose of the work was to determine level S100β protein in children with COVID-19 and investigate correlation this neurobiomarker severity age patients. Materials methods. We conducted a retrospective, cohort, observational, post-registration study. examined 88 aged 1 month 17 years laboratory-confirmed who underwent inpatient treatment at Kyiv City Children’s Clinical Infectious Diseases Hospital (Kyiv, Ukraine) 2021–2022. Children were divided according course disease into two groups: control group, which had complicated COVID-19, main group without complications. also made division by 0–12 months, 1–6, 6–10 10–17 years. laboratory indicators, data anamnesis objective examination taken account. During comprehensive routine patients on first day their stay hospital, blood serum collected for further enzyme immunoassay. CanAg S100 EIA kit (Fujirebio) working measurement range 1–3500 ng/L marker used. research carried out accordance Declaration Helsinki principles. protocol approved Local Ethics Committee institution mentioned work. Informed consent parents obtained. In study, we used statistical research, analytical methods, method empirical research. Results. When comparing groups age, from birth 12 months significant indicator (44.8 % vs. 23.3 controls), p = 0.049. conducting study D-dimer, linear found (r 0.141; 95% CI –1... 0.311; < 0.1), as well negative prothrombin index –0.204; 0.0131; 0.03) –0.184; 0.0077; 0.04). Conclusions. A between neurobiomarker, revealed. Higher indicators noted disease. tendency towards higher younger revealed, relationship neuromarkers D-dimer.